ABVC BioPharma (ABVC) AI Stock Analysis

• Market Cap: $49.09M
• Dividend Yield: N/A
• Average Volume (3M): 95.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: 56.52%
• EPS Growth: 75.22%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 24,301,088
• 10 Day Avg. Volume: 116,541
• 30 Day Avg. Volume: 95,045
• PEG Ratio: 0.02
• Price to Book (P/B): 5.62
• Price to Sales (P/S): 13.52
• P/FCF Ratio: -3.81
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 38.19
• Enterprise Value/Gross Profit: 38.19
• Enterprise Value/Ebitda: -7.58
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $2.00 ▼(-4.76% Downside)

The score is held down primarily by weak financial performance (heavy losses and ongoing cash burn) despite improved revenue and lower leverage. Technicals are mixed with slightly negative momentum, and valuation is constrained by a negative P/E and no dividend yield data.

Positive Factors

Revenue Growth

The significant revenue increase indicates strong business execution and potential for future growth, enhancing the company's market position.

Cost Reductions

Effective cost management and improved earnings per share reflect operational efficiency, supporting long-term profitability and sustainability.

Partnerships and Milestone Payments

Strong partnerships and milestone payments provide financial resources for growth without dilutive financing, enhancing strategic flexibility.

Negative Factors

High Leverage

High leverage limits financial flexibility and increases risk, potentially impacting the company's ability to invest in growth opportunities.

Negative Cash Flow

Negative cash flow indicates financial strain, limiting the company's ability to fund operations and growth internally, necessitating external financing.

Lack of Profitability

Persistent lack of profitability undermines financial stability and limits reinvestment capacity, posing a challenge to long-term viability.

ABVC BioPharma Business Overview & Revenue Model

Company Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

How the Company Makes Money

ABVC BioPharma, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates and medical devices. The company's revenue model includes licensing agreements, partnerships with other pharmaceutical companies, and potentially direct sales of successfully developed therapeutics and devices. Significant partnerships and collaborations with research institutions and healthcare organizations play a crucial role in advancing ABVC's product pipeline and can lead to milestone payments, royalties, and other income streams as products progress through clinical trials and receive regulatory approval.

ABVC BioPharma Financial Statement Overview

Summary

Revenue rebounded strongly in the TTM period and leverage is currently low (debt-to-equity ~0.12), but the overall financial profile remains weak due to deeply negative operating/EBITDA results, very large net losses (TTM net margin roughly -521%), and persistent negative operating and free cash flow indicating ongoing cash burn.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply (about +104% growth) and gross profit remains positive, indicating some improvement in top-line traction. However, profitability is still very weak: operating and EBITDA results remain deeply negative and the company continues to post large net losses, with losses multiple times revenue (TTM net margin roughly -521%). Overall, the trend shows recovering revenue but no clear path yet to sustainable earnings.

Balance Sheet

Leverage looks much improved in TTM (Trailing-Twelve-Months), with total debt relatively low versus equity (debt-to-equity ~0.12), which reduces near-term financial strain versus prior years (e.g., materially higher leverage in 2024). That said, returns on equity remain significantly negative due to ongoing losses, and the equity base appears to have changed substantially versus 2024, which can signal volatility in capitalization. The balance sheet is better positioned on leverage today, but still burdened by loss-driven erosion risk.

Cash Flow

Cash generation remains a key weakness: operating cash flow and free cash flow are negative in TTM (Trailing-Twelve-Months), continuing a multi-year pattern of cash burn. While free cash flow showed improvement versus the prior period (positive growth rate), cash flow still does not cover losses in an economically healthy way, and ongoing funding needs remain likely if current burn persists.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	797.92K	509.59K	152.43K	969.78K	355.80K	483.05K
Gross Profit	797.92K	508.83K	-149.61K	683.37K	350.71K	464.33K
EBITDA	-4.02M	-4.34M	-6.33M	-15.20M	-10.97M	-10.37M
Net Income	-4.12M	-4.90M	-7.79M	-16.42M	-12.84M	-9.79M
Balance Sheet
Total Assets	21.18M	7.54M	7.78M	10.93M	13.70M	14.77M
Cash, Cash Equivalents and Short-Term Investments	257.24K	928.55K	796.09K	1.47M	5.94M	5.00M
Total Debt	1.39M	3.20M	2.77M	3.41M	3.34M	6.77M
Total Liabilities	6.68M	6.82M	6.53M	6.34M	4.83M	8.94M
Stockholders Equity	12.06M	1.23M	1.55M	4.45M	8.84M	6.60M
Cash Flow
Free Cash Flow	-2.06M	-1.81M	-4.21M	-7.52M	-7.62M	-4.56M
Operating Cash Flow	-2.06M	-1.81M	-4.19M	-7.40M	-7.60M	-4.56M
Investing Cash Flow	-1.94M	0.00	-360.19K	-1.72M	-805.97K	-225.43K
Financing Cash Flow	4.07M	1.98M	3.87M	4.01M	10.00M	9.57M

ABVC BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Negative. The current price of 2.1 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.26, and below the 200-day MA of 2.43, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 35.14 is Neutral, neither overbought nor oversold. The STOCH value of 21.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABVC.

ABVC BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HYFT	53 Neutral	$75.64M	-2.74	-121.76%	―	-17.94%	21.43%
JSPR	52 Neutral	$41.42M	-0.25	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CAMP	49 Neutral	$191.96M	-1.54	-172.70%	―	―	5.51%
INKT	48 Neutral	$55.30M	-3.83	―	―	―	21.48%
CRVO	45 Neutral	$47.65M	-1.68	-71.42%	―	-38.81%	-76.96%
ABVC	44 Neutral	$49.09M	-8.47	-40.32%	―	56.52%	75.22%